Roche Breast Cancer Drug Appears to Greatly Extend Patients’ Lives

http://rss.nytimes.com/c/34625/f/640377/s/3ee68b3b/sc/14/l/0L0Snytimes0N0C20A140C0A90C290Cbusiness0Croche0Ebreast0Ecancer0Edrug0Eappears0Eto0Egreatly0Eextend0Epatients0Elives0Bhtml0Dpartner0Frss0Gemc0Frss/story01.htm

Perjeta, approved by the F.D.A. in 2012, prolonged median survival time about 16 months in a trial of 808 people with metastatic breast cancer.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s